Item 8.01 Other Events.
On September 7, 2021, NeuroOne Medical Technologies Corporation (the "Company")
issued a press release announcing that the Company received U.S. Food and Drug
Administration 510(k) clearance to market its Evo sEEG Electrode technology for
temporary (less than 24 hours) use with recording, monitoring, and stimulation
equipment for the recording, monitoring, and stimulation of electrical signals
at the subsurface level of the brain. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release, dated September 7, 2021
104 Cover Page Interactive Data File (embedded within Inline XBRL document).
1
© Edgar Online, source Glimpses